)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) investor relations material
Iovance Biotherapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary9 Jan, 2026
Strategic positioning and product portfolio
Leading innovator in tumor infiltrating lymphocyte (TIL) therapy for solid tumors, with two approved products: Amtagvi (lifileucel) and Proleukin (aldesleukin).
Amtagvi is the first FDA-approved one-time, individualized T cell therapy for solid tumor cancer, targeting advanced melanoma and expanding into new indications and geographies.
Over 1,000 patients have been treated with commercial and clinical TIL products, with a network of more than 85 treatment centers as of December 2025.
Broad market access with payer coverage for over 250 million patient lives and rapid financial clearance for most patients.
Modular manufacturing facility in Philadelphia supports up to 5,000 patients per year, ensuring global supply and logistics.
Clinical performance and pipeline development
Amtagvi demonstrates deep and durable responses in advanced melanoma, with a 31.4% ORR and median duration of response of 36.5 months at five-year follow-up.
Real-world data show a ~50% response rate, with higher efficacy in patients treated earlier in their disease course.
Ongoing label expansion includes frontline advanced melanoma (lifileucel + pembrolizumab), advanced NSCLC, and endometrial cancer, with multiple phase 2 and 3 trials underway.
Next-generation TIL therapies in development include PD-1 inactivated TIL (IOV-4001), IL-2 analog (IOV-3001), and IL-12 tethered TIL (IOV-5001), targeting improved efficacy and safety.
TILVANCE-301, a global phase 3 trial, is enrolling for frontline melanoma, while IOV-LUN-202 targets post-anti-PD-1 NSCLC with promising interim results.
Market opportunity and financial outlook
Solid tumors represent 91% of all cancer cases, with significant unmet needs in melanoma, NSCLC, and endometrial cancer.
The global NSCLC commercial opportunity is estimated at seven times the current melanoma market.
FY25 revenue guidance is $250M–$300M, with $307M in cash as of September 30, 2025, and a gross margin of 43% in Q3 2025.
Cash runway is projected into Q2 2027, supported by anticipated revenue growth, margin improvement, and cost control from strategic restructuring.
Organization streamlined to support improved margins, leveraging economies of scale in manufacturing and a global commercial infrastructure.
How does real-world ORR affect Amtagvi patient flow?
What is the strategic importance of the NSCLC program?
How will IOV-3001 impact Amtagvi's regimen?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Iovance Biotherapeutics earnings date
Q4 20255 Feb, 2026
Iovance Biotherapeutics
Next Iovance Biotherapeutics earnings date
Q4 20255 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Iovance Biotherapeutics Inc is a biotechnology company focused on developing cell-based immunotherapies for the treatment of cancer. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harnessing and enhancing a patient's immune cells to target and destroy cancer cells. Iovance’s research primarily targets solid tumors, aiming to offer new treatment options for patients with melanoma, cervical cancer, and other types of cancers. Its therapies are developed using advanced cell therapy technologies to address cancers that are resistant to traditional treatments. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage